Skip to main content

Advertisement

SpringerLink
Log in

Membranous nephropathy with thrombotic microangiopathy-like lesions successfully treated with tocilizumab in a patient with idiopathic multicentric Castleman disease

  • Case Report
  • Published:
CEN Case Reports Aims and scope Submit manuscript

Abstract

Idiopathic multicentric Castleman disease (iMCD) is a systemic lymphoproliferative disease involving multiple organs, including the kidneys. Membranous nephropathy (MN) has been rarely reported as a complication of iMCD. We herein report the case of a 48-year-old man with a 9-year history of iMCD that was complicated by treatment-resistant nephrotic syndrome due to MN. The first renal biopsy performed at the age of 45 years showed diffuse and global MN with a mild glomerular endothelial injury. He was treated with combined therapy of corticosteroids, immunosuppressants, and tocilizumab, an anti-interleukin-6 (IL-6) receptor monoclonal antibody, which was administered every 2–3 weeks. However, nephrotic syndrome persisted, and renal impairment slowly worsened. Serial biopsy performed at 3 years after the first biopsy confirmed advanced lesions of both MN-related and glomerular endothelial injuries. Modification of the therapeutic strategy to weekly administration of tocilizumab gradually led to the remission of proteinuria, allowing the termination of corticosteroids. Thus, the present case suggests a close link between excessive IL-6 actions and the development of glomerular lesions in iMCD. Successful treatment by strict inhibition of IL-6 actions, in this case, may provide a clue for deciding the therapeutic strategy for severe renal complications associated with iMCD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Liu AY, Nabel CS, Finkelman BS, Ruth JR, Kurzrock R, van Rhee F, Krymskaya VP, Kelleher D, Rubenstein AH, Fajgenbaum DC. Idiopathic multicentric Castleman’s disease: a systematic literature review. Lancet Haematol. 2016;3:e163–75.

    Article  Google Scholar 

  2. Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, Simpson D, Liu AY, Menke D, Chandrakasan S, Lechowicz MJ. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. 2017;129:1646–57.

    Article  CAS  Google Scholar 

  3. Kojima M, Nakamura N, Tsukamoto N, Otuski Y, Shimizu K, Itoh H, Kobayashi S, Kobayashi H, Murase T, Masawa N, Kashimura M. Clinical implications of idiopathic multicentric castleman disease among Japanese: a report of 28 cases. Int J Surg Pathol. 2008;16:391–8.

    Article  Google Scholar 

  4. Kawabata H, Kadowaki N, Nishikori M, Kitawaki T, Kondo T, Ishikawa T, Yoshifuji H, Yamakawa N, Imura Y, Mimori T, Matsumura Y. Clinical features and treatment of multicentric Castleman’s disease: a retrospective study of 21 Japanese patients at a single institute. J Clin Exp Hematopathol. 2013;53:69–77.

    Article  Google Scholar 

  5. Xu D, Lv J, Dong Y, Wang S, Su T, Zhou F, Zou W, Zhao M, Zhang H. Renal involvement in a large cohort of Chinese patients with Castleman disease. Nephrol Dial Transplant. 2012;27:3119–225.

    Article  Google Scholar 

  6. El Karoui K, Vuiblet V, Dion D, Izzedine H, Guitard J, Frimat L, Delahousse M, Remy P, Boffa JJ, Pillebout E, Galicier L. Renal involvement in Castleman disease. Nephrol Dial Transplant. 2011;26:599–609.

    Article  Google Scholar 

  7. Xie Q, Li Y, Xue J, Xiong Z, Wang L, Sun Z, Ren Y, Zhu X, Hao C. Renal phospholipase A2 receptor in hepatitis B virus-associated membranous nephropathy. Am J Nephrol. 2015;41:345–53.

    Article  CAS  Google Scholar 

  8. Larsen CP, Messias NC, Silva FG, Messias E, Walker PD. Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies. Mod Pathol. 2013;26:709–15.

    Article  CAS  Google Scholar 

  9. Stehlé T, Audard V, Ronco P, Debiec H. Phospholipase A2 receptor and sarcoidosis-associated membranous nephropathy. Nephrol Dial Transplant. 2015;30:1047–50.

    Article  Google Scholar 

  10. Furutera N, Fukunaga N, Okita J, Suzuki T, Suenaga Y, Oyama Y, Aoki K, Fukuda A, Nakata T, Uesugi N, Daa T, Hisano S, Shibata H. Two cases of idiopathic multicentric Castleman disease with nephrotic syndrome treated with tocilizumab. CEN Case Rep. 2020. https://doi.org/10.1007/s13730-020-00511-8.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Nagai K, Usui J, Noguchi K, Unai K, Hiwatashi A, Arakawa Y, Togashi A, Morito N, Saito C, Yoh K, Tsuruoka S. A case of multicentric Castleman’s disease with membranoproliferative glomerulonephritis type 3-like lesion. Pathol Int. 2011;61:686–90.

    Article  Google Scholar 

  12. Komaba H, Nakazawa T, Yamaguchi Y, Kumagai S, Fukagawa M. Interleukin-6 receptor inhibition with tocilizumab in various renal involvements associated with multicentric Castleman’s disease: a report of three cases. NDT Plus. 2008;1:423–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Zoshima T, Yamada K, Hara S, Mizushima I, Yamagishi M, Harada K, Sato Y, Kawano M. Multicentric Castleman disease with tubulointerstitial nephritis mimicking IgG4-related disease. Am J Surg Pathol. 2016;40:495–501.

    Article  Google Scholar 

  14. Ohtani H, Wakui H, Komatsuda A, Okuyama S, Masai R, Maki N, Kigawa A, Sawada K, Imai H. Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy. Nephrol Dial Transplant. 2004;19:574–9.

    Article  CAS  Google Scholar 

  15. Hamai K, Komatsuda A, Ohtani H, Miura AB. IgG subclasses in patients with membranoproliferative glomerulonephritis, membranous nephropathy, and lupus nephritis. Kidney Int. 1997;51:270–6.

    Article  Google Scholar 

  16. Kuroki A, Shibata T, Honda H, Totsuka D, Kobayashi K, Sugisaki T. Glomerular and serum IgG subclasses in diffuse proliferative lupus nephritis, membranous lupus nephritis, and idiopathic membranous nephropathy. Intern Med. 2002;41:936–42.

    Article  CAS  Google Scholar 

  17. Shimada S, Nakamichi T, Yamada G, Narumi K, Usubuchi H, Yamamoto T, Ichikawa S, Fukuhara N, Miyazaki M, Harigae H, Sato H, Ito S. Concurrent isolated IgG2-positive membranous nephropathy and malignant B-cell lymphoma. CEN Case Rep. 2018;7:248–52.

    Article  Google Scholar 

  18. Iida A, Wada Y, Hayashi J, Tachibana S, Inaba T, Iyoda M, Honda K, Shibata T. Membranous nephropathy caused by rheumatoid arthritis. CEN Case Rep. 2019;8:233–8.

    Article  Google Scholar 

  19. Leurs A, Gnemmi V, Lionet A, Renaud L, Gibier J-B, Copin M-C, Hachulla E, Hatron PY, Launay D, Fajgenbaum D, Terriou L. Renal pathologic findings in TAFRO syndrome: is there a continuum between thrombotic microangiopathy and membranoproliferative glomerulonephritis? A case report and literature review. Front Immunol. 2019;10:1489.

    Article  Google Scholar 

  20. Modesto-Segonds A, Rey JP, Orfila C, Huchard G, Suc JM. Renal involvement in POEMS syndrome. Clin Nephrol. 1995;43:342–5.

    CAS  PubMed  Google Scholar 

  21. Hung M-J, Cherng W-J, Hung M-Y, Wu H-T, Pang J-HS. Interleukin-6 inhibits endothelial nitric oxide synthase activation and increases endothelial nitric oxide synthase binding to stabilized caveolin-1 in human vascular endothelial cells. J Hypertens. 2010;28:940–51.

    Article  CAS  Google Scholar 

  22. Nakayama T, Sato W, Kosugi T, Zhang L, Campbell-Thompson M, Yoshimura A, Croker P, Johnson J, Nakagawa T. Endothelial injury due to eNOS deficiency accelerates the progression of chronic renal disease in the mouse. Am J Physiol Ren Physiol. 2009;296:F317–27.

    Article  CAS  Google Scholar 

  23. Nakayama T, Sato W, Yoshimura A, Zhang L, Kosugi T, Campbell-thompson M, Kojima H, Croker P, Nakagawa T. Endothelial von Willebrand factor release due to eNOS deficiency predisposes to thrombotic microangiopathy in mouse aging kidney. Am J Pathol. 2010;176:2198–208.

    Article  CAS  Google Scholar 

  24. Ruggieri G, Barsotti P, Coppola G, Spinelli C, Balducci A, Ventola FR, Tata MV, Marinozzi V. Membranous nephropathy associated with giant lymph node hyperplasia: a case report with histological and ultrastructural studies. Am J Nephrol. 1990;10:323–8.

    Article  CAS  Google Scholar 

  25. Tazi I, Rachid M, Quessar A, Benchekroun S. A rare association of Castleman’s disease and nephrotic syndrome. Saudi J Kidney Dis Transplant. 2011;22:116–9.

    CAS  Google Scholar 

  26. Weisenburger DD. Membranous nephropathy. Its association with multicentric angiofollicular lymph node hyperplasia. Arch Pathol Lab Med. 1979;103:591–4594.

    CAS  PubMed  Google Scholar 

  27. van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, Munshi N, Schey S, Streetly M, Pierson SK, Partridge HL. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018;132:2115–24.

    Article  Google Scholar 

  28. Lefaucheur C, Stengel B, Nochy D, Martel P, Hill GS, Jacquot C, Rossert J, Gn-Progress Study Group. Membranous nephropathy and cancer: epidemiologic evidence and determinants of high-risk cancer association. Kidney Int. 2006;70:1510–7.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Moeno Ishida and Mami Ohori for providing technical assistance with the immunofluorescent studies.

Author information

Authors and Affiliations

  1. Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-ku, Tokyo, Japan

    Takeshi Tosaki, Masahiro Okabe, Akihiro Shimizu, Kentaro Koike, Nobuo Tsuboi, Tetsuya Kawamura & Takashi Yokoo

  2. Department of Nephrology, Kameda Medical Center, Kamogawa, Japan

    Tomo Suzuki

  3. Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan

    Tomo Suzuki

  4. Department of Diagnostic Pathology, Nippon Medical School Musashi-Kosugi Hospital, Kawasaki, Japan

    Ryuji Ohashi

  5. Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan

    Shingo Yano

Authors
  1. Takeshi Tosaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masahiro Okabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tomo Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Akihiro Shimizu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kentaro Koike
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nobuo Tsuboi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tetsuya Kawamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ryuji Ohashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Shingo Yano
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Takashi Yokoo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masahiro Okabe.

Ethics declarations

Conflict of interest

The authors declare that they have no competing interests.

Research involving human participants

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

The authors declare that they have obtained the written consent from the patient discussed in the report.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tosaki, T., Okabe, M., Suzuki, T. et al. Membranous nephropathy with thrombotic microangiopathy-like lesions successfully treated with tocilizumab in a patient with idiopathic multicentric Castleman disease. CEN Case Rep 10, 265–272 (2021). https://doi.org/10.1007/s13730-020-00559-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13730-020-00559-6

Keywords

Search

Navigation